
Castle Biosciences CSTL
$ 28.2
2.29%
Quarterly report 2025-Q3
added 11-03-2025
Castle Biosciences EV/EBITDA Ratio 2011-2026 | CSTL
Annual EV/EBITDA Ratio Castle Biosciences
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| -21.2 | -142 | 24 | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 24 | -142 | -46.4 |
EV/EBITDA Ratio of other stocks in the Diagnostics research industry
| Issuer | EV/EBITDA Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Anixa Biosciences
ANIX
|
-2.25 | $ 2.91 | 2.83 % | $ 94.4 K | ||
|
Agilent Technologies
A
|
27.4 | $ 120.18 | 0.96 % | $ 36.5 B | ||
|
Centogene N.V.
CNTG
|
0.387 | - | -6.23 % | $ 30.6 M | ||
|
Aspira Women's Health
AWH
|
-2.63 | - | -6.19 % | $ 10.5 M | ||
|
Burning Rock Biotech Limited
BNR
|
-1.51 | $ 22.99 | -2.36 % | $ 241 M | ||
|
Celcuity
CELC
|
-2.38 | $ 108.3 | 0.84 % | $ 4.27 B | ||
|
Akumin
AKU
|
28.1 | - | -17.87 % | $ 25.9 M | ||
|
Fulgent Genetics
FLGT
|
2.58 | $ 14.09 | 2.18 % | $ 426 M | ||
|
Oxford Immunotec Global PLC
OXFD
|
-73.4 | - | - | $ 562 M | ||
|
Heska Corporation
HSKA
|
141 | - | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
-1.42 | - | -20.0 % | $ 1.06 M | ||
|
Charles River Laboratories International
CRL
|
22 | $ 178.99 | 1.88 % | $ 8.87 B | ||
|
Accelerate Diagnostics
AXDX
|
-5.56 | - | -61.36 % | $ 2.46 M | ||
|
IDEXX Laboratories
IDXX
|
45.3 | $ 643.83 | 1.3 % | $ 51.8 B | ||
|
Illumina
ILMN
|
70.5 | $ 130.32 | 0.59 % | $ 20.7 B | ||
|
Global Cord Blood Corporation
CO
|
-3.52 | - | - | $ 399 M | ||
|
Fluidigm Corporation
FLDM
|
-13.6 | - | 1.08 % | $ 308 M | ||
|
Genetic Technologies Limited
GENE
|
-2.67 | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
-2.67 | - | 0.12 % | $ 80.1 M | ||
|
Laboratory Corporation of America Holdings
LH
|
8.7 | $ 281.82 | -0.44 % | $ 23.4 B | ||
|
PRA Health Sciences, Inc.
PRAH
|
20.8 | - | - | $ 10.7 B | ||
|
Lantheus Holdings
LNTH
|
-187 | $ 77.77 | -1.36 % | $ 5.25 B | ||
|
Motus GI Holdings
MOTS
|
0.351 | - | -34.28 % | $ 263 K | ||
|
Biodesix
BDSX
|
-4.25 | $ 15.54 | 0.26 % | $ 2.02 B | ||
|
Biocept
BIOC
|
-26.9 | - | -13.05 % | $ 7.29 M | ||
|
Mettler-Toledo International
MTD
|
827 | $ 1 302.74 | -1.06 % | $ 26.8 B | ||
|
Myriad Genetics
MYGN
|
-17.2 | $ 5.41 | 2.27 % | $ 501 M | ||
|
Invitae Corporation
NVTA
|
-10.7 | - | - | $ 21.2 M | ||
|
NeoGenomics
NEO
|
-33.5 | $ 9.28 | -2.73 % | $ 1.19 B | ||
|
BioNano Genomics
BNGO
|
-7.71 | $ 1.13 | 0.9 % | $ 1.44 M | ||
|
Quest Diagnostics Incorporated
DGX
|
5.51 | $ 208.42 | 0.03 % | $ 23.1 B | ||
|
National Research Corporation
NRC
|
21 | $ 13.25 | -1.05 % | $ 325 M | ||
|
Danaher Corporation
DHR
|
20.1 | $ 204.05 | 0.02 % | $ 145 B | ||
|
Organovo Holdings
ONVO
|
0.992 | - | -2.3 % | $ 19.4 M | ||
|
Exact Sciences Corporation
EXAS
|
-20.8 | $ 103.38 | - | $ 19.5 B | ||
|
Bioventus
BVS
|
26.4 | $ 8.59 | -1.77 % | $ 538 M | ||
|
OPKO Health
OPK
|
25.9 | $ 1.2 | 0.42 % | $ 833 M | ||
|
DarioHealth Corp.
DRIO
|
-1.05 | $ 9.52 | -7.57 % | $ 270 M | ||
|
DexCom
DXCM
|
39.5 | $ 72.81 | -0.37 % | $ 28.4 B | ||
|
PerkinElmer
PKI
|
18.8 | - | -0.91 % | $ 14.7 B | ||
|
Pacific Biosciences of California
PACB
|
-23.8 | $ 1.61 | 5.59 % | $ 483 M | ||
|
Psychemedics Corporation
PMD
|
15.9 | - | -1.84 % | $ 15.3 M | ||
|
QIAGEN N.V.
QGEN
|
13.2 | - | - | $ 10.6 B | ||
|
ICON Public Limited Company
ICLR
|
38 | $ 109.61 | 0.84 % | $ 9.04 B | ||
|
Quotient Limited
QTNT
|
-5.32 | - | -11.32 % | $ 1.1 M | ||
|
Precipio
PRPO
|
-1.8 | $ 26.37 | 5.57 % | $ 34.2 M | ||
|
Personalis
PSNL
|
-7.07 | $ 8.92 | 2.88 % | $ 529 M | ||
|
Renalytix AI plc
RNLX
|
-32.1 | - | 5.66 % | $ 22.7 M | ||
|
CareDx, Inc
CDNA
|
-100 | $ 19.22 | 2.21 % | $ 1.02 B |